Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.59 |
| ▸ | HTR1A | P08908 | 8/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.58 |
| ▸ | HTR2C | P28335 | 7/20 | 0.52 |
| ▸ | HTR2B | P41595 | 7/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5482984 | 0.98 | SLC6A2 (0.58) | SLC6A2HTR1ASLC6A4SLC6A3HTR2C | |
| SCHEMBL3080032 | 0.90 | SLC6A2 (0.57) | SLC6A2HTR1ASLC6A4SLC6A3CYP2D6 | |
| Hydrochloric Acid SCHEMBL4095144 | 0.89 | SLC6A2 (0.56) | SLC6A2HTR1ASLC6A4SLC6A3CYP2D6 | |
| SCHEMBL3163221 | 0.87 | SLC6A2 (0.64) | SLC6A2HTR1ASLC6A4SLC6A3HTR2C | |
| SCHEMBL8271825 | 0.87 | SLC6A2 (0.64) | SLC6A2HTR1ASLC6A4SLC6A3HTR2C | |
| SCHEMBL14957210 | 0.86 | SLC6A2 (0.64) | SLC6A2HTR1ASLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL71830 | 0.85 | SLC6A2 (0.63) | SLC6A2HTR1ASLC6A4SLC6A3HTR2C | |
| Hydrochloric Acid SCHEMBL4119514 | 0.85 | SLC6A2 (0.63) | SLC6A2HTR1ASLC6A4SLC6A3HTR2C | |
| Hydrochloric Acid SCHEMBL4119212 | 0.85 | SLC6A2 (0.63) | SLC6A2HTR1ASLC6A4SLC6A3HTR2C | |
| SCHEMBL82955 | 0.76 | HRH1 (0.62) | SLC6A2HTR1ASLC6A4SLC6A3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021404-A1 | Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2007-01-25 | — | — | US | claimed |
| EP-1638939-A2 | AZA-RING DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2006-03-29 | — | — | EP | claimed |
| WO-2004113297-A9 | AZA-RING DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2005-11-24 | — | — | WO | claimed |
| WO-2004113297-A2 | AZA-RING DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2004-12-29 | — | — | WO | claimed |
| US-20070021404-A1 | Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2007-01-25 | — | — | US | disclosed |
| EP-1638939-A2 | AZA-RING DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004113297-A9 | AZA-RING DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2005-11-24 | — | — | WO | disclosed |
| WO-2004113297-A2 | AZA-RING DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021404-A1 | Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | SLC6A2 2/4885HTR1A 67/4885SLC6A4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.